Immix Biopharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the application of chimeric antigen receptor cell therapy (CAR- T) in light chain (AL) Amyloidosis and autoimmune disease. The Company's lead cell therapy asset is CAR-T NXC-201 for autoimmune disease, relapsed/refractory AL Amyloidosis, and relapsed/refractory multiple myeloma, which is being evaluated in its ongoing Phase Ib/IIa NEXICART-1 (NCT04720313) clinical trial. Its tissue specific therapeutic IMX-110 is in clinical trials as a monotherapy, and in combination with tislelizumab (BeiGene anti-PD-1 - IMMINENT-01 NCT05840835) for advanced solid tumors, such as relapsed/refractory colorectal cancer (CRC). IMX-110 in Phase Ib/IIa clinical trials, is a Tissue-Specific Therapeutic with TME Normalization, a technology that the Company is developing initially for mCRC and Soft Tissue Sarcoma (STS).

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
25-12-10	6.700 $	+1.52%	1,163,145
25-12-09	6.600 $	+7.32%	2,907,535
25-12-08	6.150 $	+10.61%	7,037,078
25-12-05	5.560 $	+14.88%	1,113,131
25-12-04	4.840 $	+16.63%	1,232,030

Delayed Quote Nasdaq, December 10, 2025 at 12:13 pm EST

More quotes

Income Statement and Estimates

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

6.600USD

Average target price

7.950USD

Spread / Average Target

+20.45%

Consensus

EPS Estimates

Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar

Real-time Estimate Cboe BZX Other stock markets 12:28:33 2025-12-10 pm EST			5-day change	1st Jan Change
6.620 ^USD	+0.30%		+61.33%	+204.32%

Dec. 07	Immix Biopharma prices offering of 19.1 million shares at $5.10 per share	RE
Nov. 12	Immix Biopharma, Inc. Appoints Michael Grabow as Chief Commercial Officer	CI

Capitalization	222M 190M 178M 166M 307M 19.92B 334M 2.06B 804M 9.44B 832M 814M 34.65B	P/E ratio 2025 *	-8.52x	P/E ratio 2026 *	-9.64x
Enterprise value	229M 197M 184M 172M 317M 20.58B 345M 2.13B 831M 9.75B 859M 841M 35.8B	EV / Sales 2025 *	-	EV / Sales 2026 *	-
Free-Float	59.75%	Yield 2025 *	-	Yield 2026 *	-

Dec. 07	Immix Biopharma prices offering of 19.1 million shares at $5.10 per share	RE
Nov. 12	Immix Biopharma, Inc. Appoints Michael Grabow as Chief Commercial Officer	CI
Nov. 07	Immix Biopharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
Sep. 18	Immix Biopharma says that 50% enrollment has already been surpassed in NEXICART-2	RE
Sep. 18	Immix Biopharma, Inc. Announces 50% Enrollment Milestone Surpassed in Its Ongoing Relapsed/Refractory AL Amyloidosis Clinical Trial, NEXICART-2	CI
Sep. 08	Immix Biopharma Gets Strategic Investment	MT
Sep. 08	Immix Biopharma announces strategic investment by Houston based Goose Capital, led by founding member Dr. Nancy T. Chang	RE
Sep. 08	Immix Biopharma, Inc. Appoints Nancy Chang, Ph.D. as A Member of the Board, Effective September 8, 2025	CI
Sep. 04	Immix Biopharma, Inc. announced that it has received $9.079982 million in funding	CI
Aug. 08	Immix Biopharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
Aug. 06	Immix Biopharma plans to partner-out other serious disease programs	RE
Aug. 06	Immix Biopharma, Inc. Announces Other Serious Diseases Strategy	CI
Jul. 11	Immix Biopharma Says NXC-201 Safety Profile Shows Absence of Neurotoxicity in Low-Volume Disease	MT

24-07-01	HC Wainwright Initiates Immix Biopharma at Buy With $7 Price Target	MT
23-02-22	Roth MKM Initiates Immix Biopharma to Buy Rating With $14 Price Target	MT

Immix Biopharma, Inc. Stock

Equities

IMMX

US45258H1068

Biotechnology & Medical Research

Valuation: Immix Biopharma, Inc.

Chart: Immix Biopharma, Inc.

Latest news: Immix Biopharma, Inc.

Analysts' recommendations: Immix Biopharma, Inc.

Press Releases: Immix Biopharma, Inc.

News in other languages: Immix Biopharma, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Immix Biopharma, Inc.

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Income Statement and Estimates

Analysts' Consensus

Quarterly revenue - Rate of surprise

Dec. 09	Immix Biopharma Announces Closing of Upsized $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants	GL
Dec. 08	Immix Biopharma : Presentation (IMMX Corporate presentation December 2025)	PU
Dec. 07	Immix Biopharma Announces Pricing of Upsized $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants	GL
Dec. 07	At ASH 2025 Oral Presentation, Immix Biopharma Reports Positive Phase 2 NXC-201 Results, Advancing Toward BLA Submission as a Potentially First- and Best-in-Class Therapy for relapsed/refractory AL Amyloidosis	GL
Dec. 02	Immix Biopharma : Presentation (IMMX Corporate presentation – November 2025)	PU

23-11-22	La FDA approuve le dossier d’essai clinique de Immix Biopharma CAR-T NXC-201, et en permet ainsi l’administration aux patients américains
23-11-22	Immix Biopharma gibt die FDA-Genehmigung des IND-Antrags für CAR-T NXC-201 bekannt, der die Verabreichung an US-Patienten ermöglicht

1 day	+0.68%
1 week	+61.33%
Current month	+57.53%
1 month	+106.64%
3 months	+205.71%
6 months	+177.80%
Current year	+204.32%

1 week	4.07	7.3
1 month	3.16	7.3
Current year	1.34	7.3
1 year	1.34	7.3
3 years	1.26	7.75
5 years	0.68	8.68
10 years	0.68	8.68

Manager	Title	Age	Since
Ilya Rachman CEO	Chief Executive Officer	53	2011-12-31
Gabriel Morris DFI	Director of Finance/CFO	39	2021-02-28
Graham Ross CTO	Chief Tech/Sci/R&D Officer	65	2021-05-31

Director	Title	Age	Since
Ilya Rachman CHM	Chairman	53	2011-12-31
Gabriel Morris BRD	Director/Board Member	39	2021-02-28
Helen Adams BRD	Director/Board Member	66	2021-05-31

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
IMMIX BIOPHARMA, INC.	+0.30%	+61.33%	+205.71%	+346.33%	222M
ARGENX SE	+0.23%	-3.60%	+32.79%	+103.22%	54.73B
INSMED INCORPORATED	+0.18%	-5.76%	+168.34%	+906.04%	41.41B
WUXI APPTEC CO., LTD.	+0.63%	+3.72%	+57.26%	+15.94%	38.87B
BIONTECH SE	-1.31%	-2.16%	-19.00%	-43.20%	23.05B
GENMAB A/S	-0.92%	-1.56%	+27.95%	-38.74%	19.29B
WUXI BIOLOGICS (CAYMAN) INC.	+0.06%	+7.01%	+76.74%	-37.70%	17.8B
AKESO, INC.	-2.18%	-2.34%	+76.04%	+184.88%	14.13B
SUMMIT THERAPEUTICS INC.	+0.29%	-7.02%	-4.95%	+505.67%	13.12B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	-3.38%	-5.93%	+116.95%	-	12.78B
Average	-0.57%	+6.34%	+73.78%	+215.83%	23.54B
Weighted average by Cap.	-0.31%	-0.63%	+63.75%	+227.73%

	2025 *	2026 *
Net sales	-	-
Net income	-25.52M -21.91M -20.49M -19.14M -35.32M -2.29B -38.43M -238M -92.58M -1.09B -95.76M -93.73M -3.99B	-30.46M -26.15M -24.46M -22.85M -42.16M -2.74B -45.87M -284M -111M -1.3B -114M -112M -4.76B
Net Debt	7.31M 6.28M 5.87M 5.48M 10.12M 657M 11.01M 68.06M 26.52M 311M 27.43M 26.85M 1.14B	-14.21M -12.2M -11.41M -10.66M -19.66M -1.28B -21.39M -132M -51.54M -605M -53.31M -52.18M -2.22B